

1 **Improvement in Inner Retinal Function in Glaucoma with Nicotinamide (Vitamin**  
2 **B<sub>3</sub>) Supplementation: A Crossover Randomised Clinical Trial**

3 **Authors:** Flora Hui, PhD<sup>1,†</sup>, Jessica Tang, MBBS(Hons) PhD<sup>1,2</sup>, Pete A Williams, PhD<sup>3</sup>, Myra  
4 B McGuinness, PhD<sup>1</sup>, Xavier Hadoux, PhD<sup>1</sup>, Robert J Casson, DPhil FRANZCO<sup>4</sup>, Michael  
5 Coote, MBBS FRANZCO<sup>1,2</sup>, Ian A Trounce PhD<sup>1,2</sup>, Keith R. Martin, DM FRCOphth<sup>1,2,5</sup>, Peter  
6 van Wijngaarden, PhD FRANZCO<sup>1,2</sup>, Jonathan G Crowston, PhD FRANZCO<sup>1,2,6,7</sup>

7  
8 <sup>1</sup>Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne,  
9 Australia

10 <sup>2</sup>Ophthalmology, Department of Surgery, University of Melbourne, Melbourne, Australia

11 <sup>3</sup>Department of Clinical Neuroscience, Division of Eye and Vision, St. Erik Eye Hospital,  
12 Karolinska Institutet, Stockholm, Sweden

13 <sup>4</sup>Ophthalmic Research Laboratories, Discipline of Ophthalmology and Visual Sciences,  
14 University of Adelaide, Adelaide, Australia

15 <sup>5</sup>Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom

16 <sup>6</sup>Centre for Vision Research, Duke-NUS Medical School, Singapore

17 <sup>7</sup>Singapore Eye Research Institute, Singapore National Eye Centre, Singapore

18 <sup>†</sup>Corresponding author

19 **Financial support:** Ophthalmic Research Institute of Australia (FH); Jack Brockhoff  
20 Foundation, Marian and E.H. Flack Trust – JBF Grant number 4354 – 2017 (FH); Jean Miller  
21 Foundation (JGC); Connie and Craig Kimberley Fund (IAT, JGC). Board of Research Faculty  
22 Funded Career position (Karolinska Institutet) (PAW). The Centre for Eye Research Australia  
23 receives operational infrastructure support from the Victorian Government. The funding  
24 organisations had no role in the design or conduct of this research.

25 **Running head:** Nicotinamide improves retinal function in glaucoma

26 **Word count:** 3691

27 **Abbreviations and Acronyms:** ATP – adenosine triphosphate, CI – confidence interval,  
28 COR – coefficient of repeatability, ERG – electroretinogram, IOL – intraocular lens, IOP –  
29 intraocular pressure, IQR – interquartile range, MD – mean deviation, MLS – mean light  
30 sensitivity, NAD<sup>+</sup> – nicotinamide adenine dinucleotide, NAM – nicotinamide, PL – placebo,  
31 POAG – primary open-angle glaucoma, PhNR – photopic negative response, PSD – pattern  
32 standard deviation, Q1 – lower quartile, Q3 – upper quartile, RGC – retinal ganglion cell,  
33 RNFL – retinal nerve fibre layer, VF – visual field, Vmax – saturating amplitude

34 **Corresponding author:**

35 Dr Flora Hui

36 Centre for Eye Research Australia

37 Level 7, Peter Howson Wing, 32 Gisborne Street

38 East Melbourne, VIC 3002, Australia

39 [f.hui@unimelb.edu.au](mailto:f.hui@unimelb.edu.au)

40 **Conflict of interest:** No conflicting relationship exists for any author.

41 **Data sharing statement:** Clinical data was collected at the Centre for Eye Research Australia  
42 in collaboration with the Royal Victorian Eye and Ear Hospital and Melbourne Eye Specialists.  
43 These data are not publicly available. Source data of graphs may be available as source files if  
44 requested. A description of the code used to analyse the electroretinogram data is described in  
45 the Methods section, and we have also published this previously (Tang et al, 2018).

46 **Abstract**

47 **Importance:** Retinal ganglion cells endure significant metabolic stress in glaucoma but  
48 maintain capacity to recover function. Nicotinamide, a precursor of  $\text{NAD}^+$ , is low in serum of  
49 glaucoma patients and its supplementation provides robust protection of retinal ganglion cells in  
50 preclinical models. However, the potential of nicotinamide in human glaucoma is unknown.

51 **Background:** To determine whether nicotinamide supplementation alongside conventional  
52 IOP-lowering therapy improves retinal ganglion cell function in glaucoma.

53 **Design:** Crossover, double-masked, randomised clinical trial. Participants recruited from two  
54 tertiary care centres.

55 **Participants:** Fifty-seven participants, diagnosed and treated for primary glaucoma, enrolled.

56 **Methods:** Participants received oral placebo or nicotinamide and reviewed six-weekly.  
57 Participants commenced 6-weeks of 1.5 grams/day then 6 weeks of 3.0 grams/day followed by  
58 crossover without washout. Visual function measured using electroretinography and perimetry.

59 **Main outcome measures:** Change in inner retinal function, determined by photopic negative  
60 response (PhNR) parameters: saturated PhNR amplitude ( $V_{\text{max}}$ ), ratio of PhNR/b-wave  
61 amplitude ( $V_{\text{max}}$  ratio).

62 **Results:** PhNR  $V_{\text{max}}$  improved beyond 95% coefficient of repeatability (COR) in 23% of  
63 participants following nicotinamide versus 9% on placebo. Overall,  $V_{\text{max}}$  improved by 14.8%  
64 [95% CI: 2.8%, 26.9%], ( $p=0.02$ ) on nicotinamide and 5.2% [-4.2%, 14.6%], ( $p=0.27$ ) on  
65 placebo.  $V_{\text{max}}$  ratio improved by 12.6% [5.0%, 20.2%], ( $p=0.002$ ) following nicotinamide,  
66 3.6% [-3.4%, 10.5%], ( $p=0.30$ ) on placebo. A trend for improved visual field mean deviation  
67 was observed with 27% improving  $\geq 1\text{dB}$  on nicotinamide and fewer deteriorating (4%)  
68 compared to placebo ( $p=0.02$ ).

69 **Conclusions:** Nicotinamide supplementation can improve inner retinal function in glaucoma.  
70 Further studies underway to elucidate the effects of long-term nicotinamide supplementation.

71 **Trial Registration:** ANZCTR trial ID: ACTRN12617000809336

72 <https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373001>


73 **Keywords:** nicotinamide, glaucoma, electroretinography, neuroprotection, vitamin B3

## 75 **Introduction**

76 Glaucoma remains the leading cause of irreversible blindness worldwide.<sup>1</sup> The disease has a  
77 complex aetiology and range of risk factors but is characterised by gradual dysfunction and loss  
78 of retinal ganglion cells (RGCs) and their axons which make up the optic nerve.<sup>2</sup> This slow,  
79 progressive loss of visual function hinders the translation of potential neuroprotective  
80 therapeutics from bench-to-bedside due to the extended time needed to determine treatment-  
81 induced changes in glaucoma progression rates. Age,<sup>1</sup> genetics,<sup>3</sup> and elevated intraocular  
82 pressure (IOP)<sup>4</sup> are all major risk factors for glaucoma yet clinically available treatment  
83 strategies target only IOP-lowering, and do not directly target the neurodegenerative events at  
84 the level of the retina and optic nerve. As many patients are refractory to IOP lowering or  
85 progress to blindness despite low IOP, neuroprotective strategies that directly target RGC health  
86 and decrease vulnerability to glaucoma-related cellular stressors are urgently needed.  
87 Accumulating evidence points to the potential for visual recovery in clinical glaucoma in  
88 response to IOP-lowering.<sup>5-7</sup> Recovery of visual function can occur soon after restoration of IOP  
89 and, as such, objective measures of visual function have potential as surrogate biomarkers of  
90 improved RGC health.

91 The photopic negative (PhNR) and positive scotopic threshold responses are parameters of the  
92 electroretinogram (ERG) that are largely generated by RGCs in the inner retina.<sup>8-10</sup> RGC  
93 function has been shown to recover after acute and chronic IOP insults even after prolonged  
94 periods of functional loss.<sup>11-13</sup> Capacity for recovery is reduced with advancing age<sup>14</sup> and can be  
95 modified by interventions such as exercise and diet restriction.<sup>15,16</sup> Using ERG protocols similar  
96 to those validated in rodent studies, we have demonstrated improvements in RGC function in  
97 humans, as early as 3-months following IOP-lowering in glaucoma.<sup>5</sup> Recent work has  
98 significantly improved repeatability of the PhNR measurement, enabling detection of subtle  
99 changes in inner retinal function.<sup>17,18</sup>

100 Several lines of evidence implicate oxidative stress and mitochondrial dysfunction in ageing<sup>19</sup>  
101 and RGC loss in glaucoma.<sup>20,21</sup> Nicotinamide adenine dinucleotide (NAD<sup>+</sup>) is an essential  
102 cofactor for ATP generation in mitochondria, and for NAD-consuming enzymes including  
103 sirtuins (Figure 1), with important roles in ageing, cell senescence, and stress resistance.<sup>22</sup>



104  
105 **Figure 1. The role of nicotinamide adenine dinucleotide (NAD<sup>+</sup>, blue) in adenosine**  
106 **triphosphate (ATP) production.** The pathways through which NAD<sup>+</sup> is created and salvaged,  
107 the major enzymes involved and the process in which NAD<sup>+</sup> supplements, nicotinamide (green)  
108 and nicotinamide riboside, may replenish NAD<sup>+</sup> levels. Complex I (yellow) within the electron  
109 transport chain, where nicotinamide adenine dinucleotide + hydrogen (NADH) is oxidized to  
110 NAD<sup>+</sup> and site of potential mitochondrial dysfunction in glaucoma. NAAD – nicotinic acid  
111 adenine dinucleotide.

112  
113 NAD<sup>+</sup> is a potent mediator of axon neuroprotection and recently, the therapeutic potential of  
114 modulating NAD<sup>+</sup> metabolism has gained widespread attention in its role in ageing and  
115 neurodegenerative disease.<sup>23-25</sup> A number of studies are currently investigating the effect of


116 NAD<sup>+</sup> repletion in a range of neurodegenerative disorders including Alzheimer's disease  
117 (NCT00580931, NCT03061474) and peripheral small fibre neuropathy (NCT03912220).  
118 Recent work has indicated that patients with primary open-angle glaucoma (POAG) have  
119 reduced serum levels of nicotinamide (NAM, the amide of vitamin B<sub>3</sub> and precursor for NAD<sup>+</sup>),  
120 indicating that systemic NAD<sup>+</sup> levels may be associated with susceptibility to glaucoma.<sup>26</sup> In  
121 support of this hypothesis, Williams et al<sup>27</sup> demonstrated that increasing retinal NAD<sup>+</sup> levels  
122 with dietary NAM or overexpression of a NAD-producing enzyme (*Nmnat1*) provided robust  
123 long-term neuroprotection of RGCs, reversed age-related transcriptomic changes, and preserved  
124 RGC function in an inherited mouse model of glaucoma (DBA/2J). These findings support the  
125 hypothesis that NAM supplementation has therapeutic potential. In addition, NAM has been  
126 safely used in a number of clinical studies with minimal adverse effects<sup>28,29</sup> and, as such, NAM  
127 supplementation may be readily translated into clinical care and complement current therapies.  
128 We therefore sought to determine whether functional improvements observed with NAM  
129 supplementation in mice could be recapitulated in humans with glaucoma in an interventional  
130 study using the ERG PhNR and visual fields (VF) as main outcome measures. This study sought  
131 to determine whether NAM, a potential neuroprotectant that targets bioenergetic insufficiency  
132 in glaucoma, could lead to a detectable improvement in inner retinal function.

133

## 134 **Methods**

### 135 **Study Design, Participants**

136 This study was a prospective, double-masked, randomized, crossover clinical trial conducted in  
137 Melbourne, Australia between October 2017 and January 2019. The study schedule is presented  
138 in Figure 2.



139

140 **Figure 2. Study schedule.** BMI – body mass index, ERG – electroretinogram, IOP – intraocular  
141 pressure, MAP – mean arterial pressure, NAM – nicotinamide, OCT – optical coherence  
142 tomography, VF – visual fields.

143

144 All procedures were approved by the Human Research Ethics Committee at the Royal Victorian  
145 Eye and Ear Hospital (17/1339H). Written informed consent was obtained from all participants  
146 prior to all procedures. Participants were recruited from public outpatient and private  
147 ophthalmology clinics (Royal Victorian Eye and Ear Hospital, Melbourne Eye Specialists). All  
148 testing was performed at the Centre for Eye Research Australia. Inclusion criteria included adult  
149 participants diagnosed and treated for glaucoma by a sub-specialist ophthalmologist, and with  
150 visual acuity of at least 6/18. Participants were required to have performed a reliable VF (SITA-  
151 Standard 24-2, HFA II-750i, Carl Zeiss Meditec AG, Germany) in the last 6 months, with <33%  
152 fixation losses, false positives and false negatives.<sup>30</sup> Eligible participants had reproducible VF



153 defects of at least 3 neighbouring points with a sensitivity below the age-matched normal (total  
154 deviation) with a probability of <2%.<sup>31</sup> Where both eyes were eligible, the eye with the better  
155 VF was chosen.

156 Exclusion criteria included pregnancy/breastfeeding, allergy to NAM/niacin, history of cancer  
157 in the last 5 years (except treated basal or squamous cell carcinoma), liver disease or stomach  
158 ulcers. Ophthalmic exclusion criteria included intraocular surgery in the past 6 months  
159 (uncomplicated cataract surgery within the last 3 months) and diseases known to affect retinal  
160 function (e.g. age-related macular degeneration, diabetic retinopathy).

161

162 As this study involved high-dose NAM, an accelerated dosing protocol was used to facilitate  
163 tolerability. Participants were randomised 1:1 with randomly selected block sizes of 4, 6 and 8  
164 using a computer-generated list to the intervention in either the first or second study period. The  
165 intervention consisted of a 6-week course of NAM (Insolar®, 0.5 g NAM tablet, Blackmores,  
166 NSW, Australia) of 1.5 g/day followed by 6 weeks of 3.0 g/day, (1.5 g twice a day, morning and  
167 evening). Placebo (PL) tablets were manufactured to match the appearance and texture of the  
168 active treatment (Pharmaceutical Packaging Professionals, Melbourne, Australia). Placebo and  
169 active treatment bottles were identical and coded with unique numerical identifiers. Participants  
170 randomised to receive placebo also doubled the number of tablets after 6 weeks to ensure they  
171 remained masked. Treatment was dispensed by the study coordinator at the conclusion of Visit  
172 1 following capture of baseline measurements. Participants, treating physicians, certified  
173 assessors and biostatisticians were masked to treatment allocation. The NAM dosage of 3.0  
174 g/day was based on that used in preclinical studies,<sup>27</sup> other published<sup>28</sup> and ongoing human trials  
175 of NAM treatment (NCT00580931, NCT03061474).

176

177 After 12 weeks, participants crossed over without washout, such that those previously on  
178 placebo treatment commenced NAM and vice versa. A washout was deemed unnecessary as  
179 any effect from NAM was assumed to be undetectable by the time of the next review visit.

180 Treatment was taken in conjunction with any glaucoma therapies participants were already  
181 using. To monitor treatment adherence, participants were asked to bring remaining tablets to  
182 each study visit and tablets were manually counted by the study coordinator. A minimum  
183 adherence rate of 70% was acceptable, equating to no more than two missed doses a week.

#### 184 **Clinical Testing**

185 All participants were seen at baseline (Visit 1), and reviewed 6-weekly ( $\pm 2$  weeks). At each visit,  
186 participants underwent a standard clinical examination, including measurement of visual acuity  
187 (EDTRS letters), IOP (Icare® PRO, Icare Finland Oy, Finland), blood pressure (HEM-7322,  
188 Omron Healthcare, Japan) and slit lamp examination. Standard automated perimetry was  
189 performed on the study eye (SITA-Standard 24-2, HFA II-750i, Carl Zeiss Meditec AG,  
190 Germany) and pupils were dilated (to  $\geq 6$  mm) using 0.5% tropicamide and 2.5% phenylephrine  
191 (Bausch and Lomb, NSW, Australia). Participants were light-adapted for at least 10 minutes  
192 before photopic ERG recording. ERGs were recorded with custom-made DTL-like electrodes  
193 using silver impregnated fibre (22/1 dtex, Shieldex trading, NY, USA) and a handheld device  
194 (RETeval™, LKC Technologies, MD, USA). Reference and ground gold-cup electrodes (Grass  
195 Technologies, Astro-Med Inc., RI, USA) were placed at the temple and forehead respectively.  
196 For optimal PhNR recording, a series of red flashes (621 nm, 16 luminous energies between  
197  $0.07$ - $12.56$  cd.s/m<sup>2</sup>, 50 sweeps, 2 Hz flash interval,<sup>32</sup> Figure 3A) on a blue background (470 nm,  
198  $10$  photopic cd/m<sup>2</sup>) was used. Stimuli were calibrated using the ILT-1700 radiometer  
199 (International Light Technologies, MA, USA) with a photopic filter. Participants underwent  
200 optical coherence tomography (OCT) to measure retinal nerve fibre layer (RNFL) thickness  
201 (Spectralis SD-OCT, Heidelberg Engineering, Dossenheim, Germany).

#### 202 **Study Objectives**


203 The primary objective was to evaluate the change in retinal function as measured by ERG and  
204 VF parameters after 12 weeks of high-dose NAM supplementation compared to placebo.

205 Specifically, changes from baseline and placebo in PhNR saturating amplitude (PhNR Vmax),  
206 PhNR/b-wave ratio (Vmax ratio) and VF indices (mean deviation, MD; pattern standard  
207 deviation, PSD; mean light sensitivity, MLS) were analysed. Secondary objectives included  
208 changes to RNFL thickness, IOP and mean arterial pressure (MAP).

### 209 **Data analysis**

210 ERG waveforms were processed as described previously.<sup>18</sup> In brief, custom-written Matlab®  
211 scripts (R2018b, Mathworks, MA, USA) were used to process raw ERG traces. ERG  
212 waveforms were processed by an assessor masked to participant characteristics, treatment group  
213 and timepoint of measurement. First, a bandpass filter (0.3 – 300 Hz) was applied. The raw data  
214 was detrended with a 3<sup>rd</sup> order polynomial, which was shown to provide the most robust PhNR  
215 signal.<sup>18</sup> Amplitudes and implicit times of the a-wave, b-wave (from a-wave trough to b-wave  
216 peak) and PhNR (minimum from baseline to trough) were  
217 extracted.

218 Amplitudes of the b-wave and PhNR (Figure 3B) across the luminance series were modelled  
219 using a saturating hyperbolic function,<sup>33</sup> defined as  $V(I) = V_{max} * I^n / (I^n + K^n)$ , where V (μV) is  
220 the amplitude as a function of luminous exposure (I), Vmax the saturating amplitude (μV), K  
221 the semi-saturation constant (1/K is the sensitivity) and n the slope (Figure 3C-D). For the  
222 PhNR, n was fixed at 1.2 (consistent with our pilot data, and similar to others).<sup>34,35</sup> Further, the  
223 PhNR Vmax was analysed as a ratio to the b-wave Vmax (Vmax ratio) to account for any  
224 changes to the b-wave between sessions.



225

226 **Figure 3. Electretinogram (ERG) analysis method.** A. Representative ERG luminance-  
227 response series showing every second luminance step, B. ERG parameters of interest, C.  
228 Representative b-wave luminance-response function data (circles) and model derived from a  
229 saturating hyperbolic function (line), D. Representative PhNR luminance-response function  
230 (circles), corresponding model (line) and model parameters: Vmax (saturating amplitude), n  
231 (slope) and K (semi-saturation constant).

232

233 In addition to VF MD and PSD, the mean light sensitivity (MLS) was calculated as the average  
234 of all perimetric sensitivity values on a 24-2 visual field (excluding one point above and below  
235 the blind spot). Visual field parameters are conventionally expressed in logarithmic decibel (dB)  
236 scale, however, these were converted to a linear scale (1/lambert) where,  $dB = 10 \cdot$   
237  $\log(1/lambert)$  before correlating with other measures.<sup>36,37</sup> The proportion of participants with

238 a  $\geq 1$  dB change in MD and PSD in NAM and placebo groups were determined and compared  
239 using Fisher's exact test.

#### 240 **Statistical Analysis**

241 Data from one eye per participant were included in the analyses. Prior to study commencement,  
242 sample size was calculated based on results of previous work investigating short-term changes  
243 in PhNR Vmax ratio following IOP reduction (under review). Assuming an attrition rate of 20%,  
244 it was estimated that 48 eyes were required to achieve 80% power to detect a difference  
245 between treatment periods with an effect size of 0.56 for Vmax ratio and two-sided hypothesis  
246 test with an  $\alpha$  level of 0.05.

247 The primary analysis set included participants who attended all study visits. Statistical analyses  
248 were conducted with the statistician masked to intervention using Stata (SE version 15.1, Texas,  
249 US). Treatment adherence was compared between randomisation groups using the Wilcoxon  
250 rank-sum test. As a washout period was not utilised, a pre-test for carryover effects was  
251 conducted for each parameter.<sup>38</sup> The within-participant sum of values for each parameter was  
252 calculated by adding change from baseline values observed under placebo to those under NAM  
253 and compared between randomisation groups using two-sample t-test. To test for a period effect,  
254 the within participant difference (NAM-PL) was compared between treatment groups using  
255 linear regression, adjusting for baseline values of each parameter. The treatment effect for each  
256 parameter was assessed following the high-dose period by examining the magnitude and  
257 direction of the within-participant difference via linear regression, with adjustment for mean-  
258 centred baseline values. Values were analysed in original units of measurement. If a statistically  
259 significant treatment effect was found at 12-weeks for any endpoint, then the 6-week timepoint  
260 was also assessed. Changes in PhNR parameters were also compared to the 95% coefficient of  
261 repeatability (COR) established from our previous work.<sup>17</sup>

262

263 Missing ERG values were associated with fatigue or persistent muscle twitch during recordings  
264 that could not be ameliorated with post-hoc signal processing. Values were multiply imputed  
265 (25 imputed datasets) using fully conditional specification (chained equations) with a univariate  
266 linear regression imputation model to reduce bias and maintain statistical power. In addition to  
267 the imputation variables, imputation models included demographics, clinical data and study  
268 group. As a sensitivity analysis, complete-case analyses were performed using the per-protocol  
269 set (n = 43) which only included participants who had non-missing data. Results are shown as  
270 mean and [95% confidence interval], unless stated otherwise.


271

## 272 **Results**

### 273 **Participants**

274 Among 94 participants assessed after medical record screening, 57 were randomised into the  
275 study, of which 49 (86%, 65.5±10.0 years, 39% female) completed the study. The participant  
276 flow chart is presented in Figure 2 and baseline characteristics of the participants included in the  
277 primary analysis in Table 1.

278



279

280 **Figure 4. CONSORT diagram.** Participants were randomised to receive placebo first or  
281 nicotinamide first. Primary analysis set defined as participants who received both interventions  
282 and attended all visits. Per-protocol set defined as a subset of the primary analysis set,  
283 excluding any participants with missing data on outcome variables (n = 6). Participants lost to  
284 follow-up (n = 4), participants discontinuing intervention (n = 4). AE – adverse event, SE – side  
285 effect.

286

287

288

289

290

291

292

293

294

295 **Table 1. Baseline characteristics for participants in the primary analysis by treatment group**  
 296 **(n = 49).**

	<b>Placebo first</b> (n = 23)	<b>Nicotinamide first</b> (n = 26)
	n (%)	n (%)
<b>Sex</b>		
Female	10 (43%)	8 (31%)
Male	13 (57%)	18 (69%)
<b>Eye tested</b>		
Left	11 (48%)	16 (62%)
Right	12 (52%)	10 (38%)
<b>Presence of IOL</b>		
No	12 (52%)	14 (54%)
Yes	11 (48%)	12 (46%)
<b>Glaucoma diagnosis</b>		
POAG	14 (61%)	16 (62%)
CACG	5 (22%)	3 (12%)
NTG	2 (9%)	5 (19%)
PXF	1 (4%)	2 (8%)
PDG	1 (4%)	0 (0%)
	<b>Mean (SD)</b>	<b>Mean (SD)</b>
Age (years)	67.01 (2.05)	65.30 (2.14)
Visual acuity (logMAR)	0.01 (0.14)	-0.01 (0.11)
Intraocular pressure (mmHg)	13.6 (2.7)	14.5 (3.3)
ERG b-wave fitting parameter: n <sup>†</sup>	1.32 (0.16)	1.29 (0.17)
ERG b-wave Vmax (μV) <sup>†</sup>	108.87 (27.48)	99.00 (29.75)
ERG b-wave fitting parameter: 1/K <sup>†</sup>	1.22 (0.30)	1.12 (0.41)
	<b>Median (Q1, Q3)</b>	<b>Median (Q1, Q3)</b>
Mean arterial pressure (mmHg) <sup>†</sup>	92.17 (85.00, 96.00)	95.67 (88.17, 98.67)
ERG PhNR fitting parameter: 1/K <sup>†</sup>	2.40 (1.24, 3.64)	1.64 (1.27, 2.68)
ERG PhNR Vmax (μV) <sup>†</sup>	15.30 (11.10, 20.58)	11.39 (9.31, 13.49)
PhNR Vmax/b-wave Vmax ratio <sup>†</sup>	0.14 (0.11, 0.20)	0.12 (0.10, 0.14)
Visual field MD (24-2) dB	-5.46 (-7.20, -1.10)	-4.51 (-8.37, -1.84)
Visual field PSD (24-2) dB	6.77 (2.37, 9.85)	5.89 (3.06, 9.28)

<sup>†</sup>Missing values in Groups 1 and 2, respectively: ERG b-wave fitting parameter: n, maximum amplitude and fitting parameter: 1/K (n=2 and 3), mean arterial pressure (n=5 and 2), ERG PhNR (μV), fitting parameter: 1/K (n=3 and 3), PhNR Vmax/b-wave Vmax ratio (n=3 and 3).  
 ERG – electroretinogram, IOL – intraocular lens, MD – mean deviation, NTG – normal tension glaucoma, POAG – primary open-angle glaucoma, PDG – pigment dispersion glaucoma, PhNR – photopic negative response, PSD – pattern standard deviation, PXFG – pseudoexfoliative glaucoma, Q1 – lower quartile, Q3 – upper quartile, SD – standard deviation, Vmax – saturated amplitude.

297

298 Majority of participants had primary open angle glaucoma (POAG, 63%), then chronic angle  
 299 closure glaucoma (16%) and normal tension glaucoma (12%). Adherence rates were high for  
 300 both NAM and placebo, with >94% adherence to NAM, demonstrating the high tolerability of



301 both low and high-dose NAM supplementation (Table 2). Only two participants (3%) were non-  
 302 adherent on NAM and removed from analysis after failing to attend all study visits.

303

304 **Table 2. Distribution of days from baseline to follow-up for participants included in the**  
 305 **primary analysis and adherence rates (%) at each visit. Treatment group 1 received placebo**  
 306 **(PL) first, Treatment group received nicotinamide (NAM) first. P-values derived from Wilcoxon**  
 307 **rank-sum test to test for differences in adherence between groups, n = 49 in total.**

Visit no.	Treatment group	Days from baseline			Adherence (%)		
		Target	Mean	SD	Median	[Q1, Q3]	p-value
2 (6 weeks)	Treatment group 1, PL	42	42.5	6.2	97.6	[88.1, 100.0]	0.80
	Treatment group 2, NAM	42	42.2	5.0	97.6	[90.5, 100.0]	
3 (12 weeks)	Treatment group 1, PL	84	85.6	5.0	95.2	[89.7, 99.2]	0.70
	Treatment group 2, NAM	84	85.4	5.3	94.4	[91.5, 96.0]	
4 (18 weeks)	Treatment group 1, NAM	126	126.8	5.7	100.0	[97.6, 100.0]	0.89
	Treatment group 2, PL	126	130.4	8.7	100.0	[92.9, 100.0]	
5 (24 weeks)	Treatment group 1, NAM	168	171.0	6.3	96.6	[93.7, 98.7]	0.46
	Treatment group 2, PL	168	169.9	10.5	94.0	[90.5, 99.2]	

NAM – nicotinamide, PL – placebo, Q1 – lower quartile, Q3 – upper quartile, SD – standard deviation


### 308 **Improvement in Retinal Ganglion Cell Function Following Nicotinamide Treatment**

309 At the 12-week visit, significant improvements in inner retinal function were found in the high-dose  
310 NAM arm, with 23% (PhNR Vmax) and 21% (Vmax ratio) of the group improving beyond the  
311 respective 95% COR for each measure. Fewer participants on placebo demonstrated improvement  
312 (PhNR Vmax: 9%; Vmax ratio: 14%). Some participants deteriorated beyond the COR (9% on  
313 placebo, 7% on NAM had a reduced Vmax; 5% on placebo, 2% on NAM had a reduced Vmax ratio).  
314 A significant difference in overall treatment effect was found for both Vmax ratio (NAM-PL: 0.01  
315 [0.002, 0.025],  $p = 0.02$ ) and PhNR Vmax (NAM-PL: 1.35  $\mu\text{V}$  [0.159, 2.551],  $p = 0.03$ , Figure 5A-B,  
316 Supplementary Table 1). PhNR sensitivity (1/K) did not change with treatment ( $p = 0.41$ ). Overall  
317 there was 12.6% [5.0, 20.2] ( $p = 0.002$ , Figure 5C) improvement in Vmax ratio between baseline and  
318 12-weeks following NAM compared to 3.6% [-3.4, 10.5] ( $p = 0.30$ ) with placebo (between group  
319 difference 9.0%,  $p = 0.03$ ). PhNR Vmax improved by 14.8% [2.8, 26.9] ( $p = 0.02$ , Figure 5D) on  
320 NAM, compared to 5.2% [-4.2, 14.6] ( $p = 0.27$ ) on placebo (between group difference 9.6%,  $p =$   
321 0.04). There was no evidence of carryover or period effects (Supplementary Tables 1 & 2) and  
322 inference was unchanged in the sensitivity analyses of the complete-case set after omitting  
323 participants with missing ERG data (Supplementary Table 2). In addition, no significant changes were  
324 noted at 6-weeks with low-dose NAM or placebo. There was no evidence of a correlation between the  
325 PhNR treatment effect and age, sex, or BMI (Supplementary Figure 1).

326

327 In addition, there was no evidence of a treatment effect on ERG measures of outer retinal function  
328 including the a-wave (photoreceptor function, Figure 5E-F) and b-wave (bipolar cell function,  
329 Figure 5G-H) amplitudes or implicit times between NAM and placebo. No differences were found for  
330 any b-wave fitting parameters between NAM and placebo groups following the low or high-dose  
331 periods (Supplementary Table 1).

332



333


334 **Figure 5. Significant improvement in the photopic negative response (inner retinal function) at 12-**  
 335 **weeks post nicotinamide intervention. A. Difference in Vmax ratio between nicotinamide (NAM) and**  
 336 **placebo (PL) at 6-weeks (NAM<sub>6</sub> - PL<sub>6</sub>, circles) and 12-weeks (NAM<sub>12</sub> - PL<sub>12</sub>, diamonds) showing**  
 337 **significant increase at NAM<sub>12</sub> ( $p = 0.02$ ), B. PhNR Vmax (μV) showing a significant increase at**

338 *NAM*<sub>12</sub> ( $p = 0.03$ ), C. *Vmax* ratio expressed as relative change from baseline (%) for nicotinamide  
339 (blue) and placebo (pink) at 6 and 12-weeks, with a significant change at *NAM*<sub>12</sub> ( $p = 0.002$ , one  
340 sample *t*-test), D. PhNR *Vmax* (*NAM*<sub>12</sub>,  $p = 0.02$ ), E-F. Luminance-response series for the a-wave and  
341 b-wave. No significant difference in a-wave amplitude and implicit time (photoreceptor) following  
342 placebo and nicotinamide treatment after low dose (6-weeks, circles) or high dose periods (12-weeks,  
343 diamonds). G-H. No significant change in b-wave amplitudes and implicit times (bipolar cell)  
344 following treatment; mean  $\pm$  95% CI,  $n = 43$ . Base – baseline, *NAM*<sub>6</sub> – nicotinamide at 6-weeks,  
345 *NAM*<sub>12</sub> – nicotinamide at 12-weeks, *PL*<sub>6</sub> – placebo at 6-weeks, *PL*<sub>12</sub> – placebo at 12-weeks.

346

#### 347 **Perimetric Changes with Nicotinamide**

348 There were no significant differences in global VF indices between treatment groups (Supplementary  
349 Table 1). After 12 weeks of NAM, average MD was no different to placebo (NAM-PL: 0.10 dB [-  
350 0.33, 0.53],  $p = 0.63$ , Figure 6A). Similarly, PSD reduced only slightly with NAM (NAM-PL: -0.25  
351 dB [-0.63, 0.14],  $p = 0.20$ , Figure 6B). Changes in MD and PSD scores for each individual are shown  
352 in Figure 6A-B. A greater proportion of participants had an increase in MD by  $\geq 1$  dB from baseline  
353 following high-dose NAM compared to placebo (27% vs. 16%) and fewer patients taking high-dose  
354 NAM had a decrease by  $\geq 1$  dB compared to placebo (4% vs 12%,  $p = 0.02$ , Figure 6C). This was not  
355 evident for PSD, where a similar proportion of participants had an increase or decrease by  $\geq 1$  dB  
356 following NAM and PL ( $p = 0.61$ , Figure 6D). A moderate positive correlation was found between  
357 changes in PhNR *Vmax* and VF MD at 12 weeks (Figure 6E-F) for both placebo (*Pearson's*  $r = 0.34$ ,  
358 [0.05, 0.57],  $p = 0.02$ ) and NAM treatment (*Pearson's*  $r = 0.50$ , [0.24, 0.70],  $p = 0.0006$ ). There was  
359 also evidence of a moderate positive correlation between PhNR *Vmax* and VF MLS (Figure 6G-H)  
360 with placebo (*Pearson's*  $r = 0.37$ , [0.09, 0.60],  $p = 0.01$ ) and NAM (*Pearson's*  $r = 0.54$ , [0.28, 0.72],  
361  $p = 0.0002$ ).



362

363 **Figure 6. Changes in visual field (VF) parameters after treatment.** A. Time-series plots of the  
364 difference in VF mean deviation (MD, dB) between nicotinamide (NAM) and placebo (PL) groups at  
365 6 and 12- weeks for each individual, B. Difference in VF pattern standard deviation (PSD, dB)  
366 between NAM and placebo groups at 6 and 12- weeks, C. Proportion of participants (%) who

367 demonstrated an improvement (green) or worsening (red) of VF MD by  $\geq 1$  dB compared to baseline  
368 for NAM and placebo groups (Fisher's exact test,  $p = 0.02$ ), D. Proportion of participants (%) who  
369 demonstrated an improvement (green) or worsening (red) of VF PSD by  $\geq 1$  dB compared to baseline,  
370 E. Linear positive correlation between VF MD (1/lambert) and the photopic negative response  
371 saturated amplitude (PhNR Vmax,  $\mu V$ ) after 12-weeks of placebo (Pearson's  $r = 0.34$ ,  $p = 0.02$ ).  
372 Dashed lines show where VF MD in dB units (0, -3 and -6 dB) are located, F. Correlation between  
373 VF MD (1/lambert) and PhNR Vmax after 12-weeks of NAM (Pearson's  $r = 0.50$ ,  $p = 0.0006$ ), G.  
374 Correlation between VF mean light sensitivity (MLS, 1/lambert) and PhNR Vmax after 12-weeks of  
375 placebo (Pearson's  $r = 0.37$ ,  $p = 0.01$ ), H. Correlation between VF MLS and PhNR Vmax after 12-  
376 weeks of NAM (Pearson's  $r = 0.54$ ,  $p = 0.0002$ );  $n = 49$ . Base – baseline, NAM<sub>6</sub> – nicotinamide at 6-  
377 weeks, NAM<sub>12</sub> – nicotinamide at 12-weeks, PL<sub>6</sub> – placebo at 6-weeks, PL<sub>12</sub> – placebo at 12-weeks.  
378

### 379 **IOP and RNFL Thickness Unchanged**

380 There was no evidence of a difference between placebo and NAM in IOP, MAP or VA  
381 (Supplementary Table 1). IOP was  $13.8 \pm 4.1$  mmHg (mean  $\pm$  SD) following NAM compared to  $13.4$   
382  $\pm 2.4$  mmHg following placebo (mean adjusted NAM-PL: 0.2 mmHg [-0.58, 1.003],  $p = 0.59$ ).  
383 Overall, there was no change in RNFL thickness. At 12-weeks, the difference in RNFL thickness  
384 compared to baseline was, NAM:  $-0.3 \pm 2.9$   $\mu m$  compared to placebo:  $0.4 \pm 2.4$   $\mu m$  (mean  $\pm$  SD,  $p =$   
385 0.11).

### 386 **Adverse effects**

387 In this study, high-dose NAM was well tolerated, the most common side effects being mild  
388 gastrointestinal discomfort (constipation or soft stools; 10.5%), nausea (5.3%) and headaches (3.5%).  
389 In the placebo group, 12.3% of participants reported difficulty in tablet swallowing, and 7.0%  
390 reported gastrointestinal discomfort. One participant withdrew after experiencing tinnitus whilst on  
391 placebo treatment. All symptoms resolved after participants ceased treatment.

392

393

394 **Discussion**

395 We provide evidence that NAM can lead to an early improvement in inner retinal function in a  
396 significant proportion of IOP-treated glaucoma patients after 12-weeks of supplementation. The  
397 majority of individuals whose PhNR parameters improved beyond 95% COR also improved in VF  
398 MD. Overall, NAM was well tolerated with an adherence rate of >94%. As systemic NAM levels  
399 have been shown to be reduced in patients with POAG,<sup>26</sup> NAM supplementation may be a convenient,  
400 safe, and cost-effective therapy in conjunction with existing IOP-lowering strategies. A longer-term  
401 study is being planned to determine whether these functional improvements are sustained and  
402 associated with delayed glaucoma progression.

403

404 There is growing evidence that impairments in visual function that occur in experimental and clinical  
405 glaucoma may recover following IOP-lowering<sup>5,6,39-41</sup> or in response to the provision of bioenergetic  
406 substrates.<sup>7,42</sup> A number of reports have shown short-term improvement in contrast sensitivity and VF  
407 parameters in response to IOP-lowering,<sup>6,41,43</sup> and some studies indicate that these improvements in  
408 visual function are sustained for extended periods.<sup>44</sup> Gandolfi et al showed significant improvements  
409 in contrast sensitivity 3-9 months after trabeculectomy, which persisted for three years.<sup>6</sup> Caprioli and  
410 colleagues also demonstrated improved sensitivity on a point-wise VF analysis with long-term  
411 improvement in 44% of VF locations, five years after trabeculectomy.<sup>44</sup> Studies have also provided  
412 evidence of ERG improvement following glaucoma treatment. Improvements in pattern  
413 electroretinography (PERG) were seen 3-months post-trabeculectomy<sup>39</sup> and following oral  
414 acetazolamide.<sup>40</sup> Niyadurupola et al demonstrated increased PhNR amplitude following a >25% IOP  
415 reduction.<sup>5</sup> There is less evidence supporting visual recovery by means other than IOP-lowering.  
416 Casson and colleagues demonstrated that elevating vitreous glucose levels temporarily improved  
417 contrast sensitivity in pseudophakic individuals with POAG, in response to elevations in vitreous  
418 glucose levels.<sup>7</sup> In the present study, oral supplementation with the metabolic substrate, NAM, was  
419 associated with a 14.8% [2.8%, 26.9%] improvement in PhNR Vmax amplitude and 12.6% [5.0%,

420 20.2%] improvement in Vmax ratio. Importantly, these effects were independent of IOP. This raises  
421 the prospect that oral NAM supplementation may serve as an adjunct to IOP-lowering therapies.

422

423 NAD<sup>+</sup> depletion is observed in many tissues with advancing age<sup>45</sup> and serum levels of NAM decline  
424 in aged POAG patients.<sup>26</sup> The mechanisms by which NAD<sup>+</sup> may improve RGC function are not  
425 known but work in animal models suggest that maintenance of mitochondrial integrity and function is  
426 a key factor.<sup>25,27,46,47</sup> High-dose NAM supplementation in DBA/2J glaucoma-model mice prevented  
427 RGC soma loss, RNFL thinning, age-related transcriptional and structural changes in mitochondria  
428 and preserved RGC function as measured with PERG.<sup>27,46</sup> NAM was protective as a prophylactic and  
429 therapeutic intervention in a dose-dependent manner. A similar level of neuroprotection was observed  
430 with the overexpression of NAD<sup>+</sup> biosynthetic enzyme, *Nmnat1* in RGCs.<sup>27</sup> A synergistic effect was  
431 found with gene therapy and NAM. Human clinical studies have not previously examined the effect  
432 of NAM supplementation on visual function in glaucoma.

433

434 NAM is the amide form of vitamin B<sub>3</sub> yet is erroneously referred to as vitamin B<sub>3</sub> in much of the  
435 scientific and medical literature. In these contexts, vitamin B<sub>3</sub> encapsulates multiple compounds  
436 including niacin/nicotinic acid, which have known ocular and systemic side effects at high doses.<sup>48</sup>  
437 However, NAM supplements are widely commercially available and are relatively safe. The most  
438 common adverse effects reported in prior clinical studies of high-dose NAM (1.5-6 g/day) were skin  
439 flushing and nausea (≤1.5%).<sup>29</sup> Longitudinal studies will reveal the tolerability of long-term high-dose  
440 NAM supplementation.

441

442 We enrolled participants already treated for glaucoma with well-controlled IOP. As IOP was  
443 unchanged by oral NAM treatment, the observed effect of NAM on inner retinal function is unlikely  
444 to be mediated through changes in IOP. Instead, our findings suggest metabolic rescue of RGCs as a  
445 putative mechanism of NAM action. We hypothesise that NAM supplementation may benefit eyes  
446 with elevated IOP, which is associated with increased RGC metabolic stress and dysfunction.<sup>2,12</sup> The  
447 NAM dosage used in our study was derived empirically from preclinical work and clinical trials of the



448 supplement for other indications. Therefore, it is possible that this dose was sub-optimal and that a  
449 single dose is not ideal for all, as pharmacokinetics and pharmacodynamics will differ, for example  
450 due to age, sex, or weight.<sup>49</sup> However, we did not observe a correlation between treatment effect and  
451 baseline demographics. Although a washout period was not utilized, there was no evidence of  
452 carryover effects, potentially due to the short plasma half-life of NAM in humans (3.5 hours after a  
453 dose of 25 mg/kg).<sup>50</sup>

454

455 For the first time, we have provided evidence that oral NAM supplementation leads to an early and  
456 measurable improvement in inner retinal function in glaucoma patients already taking IOP-lowering  
457 medication. A larger clinical trial of long-term NAM treatment is now warranted to explore whether  
458 these effects are sustained and predict a slowing in glaucoma progression.

459

460 **Acknowledgements:** Professor David Crabb for his advice on visual field analyses.

461

462 **References**

- 463 1. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and  
464 projections of glaucoma burden through 2040: a systematic review and meta-analysis. *Ophthalmology*  
465 2014; **121**: 2081-90.
- 466 2. Alqawlaq S, Flanagan JG, Sivak JM. All roads lead to glaucoma: Induced retinal injury cascades  
467 contribute to a common neurodegenerative outcome. *Exp Eye Res* 2019; **183**: 88-97.
- 468 3. Wiggs JL, Pasquale LR. Genetics of glaucoma. *Hum Mol Genet* 2017; **26**: R21-R7.
- 469 4. Bengtsson B, Leske MC, Hyman L, Heijl A. Fluctuation of intraocular pressure and glaucoma  
470 progression in the early manifest glaucoma trial. *Ophthalmology* 2007; **114**: 205-9.
- 471 5. Niyadurupola N, Luu CD, Nguyen DQ, Geddes K, Tan GX, Wong CC, Tran T, Coote MA, Crowston  
472 JG. Intraocular pressure lowering is associated with an increase in the photopic negative response  
473 (PhNR) amplitude in glaucoma and ocular hypertensive eyes. *Invest Ophthalmol Vis Sci* 2013; **54**:  
474 1913-9.
- 475 6. Gandolfi SA, Cimino L, Sangermani C, Ungaro N, Mora P, Tardini MG. Improvement of spatial  
476 contrast sensitivity threshold after surgical reduction of intraocular pressure in unilateral high-tension  
477 glaucoma. *Invest Ophthalmol Vis Sci* 2005; **46**: 197-201.
- 478 7. Casson RJ, Han G, Ebnetter A, Chidlow G, Glihotra J, Newland H, Wood JP. Glucose-induced  
479 temporary visual recovery in primary open-angle glaucoma: a double-blind, randomized study.  
480 *Ophthalmology* 2014; **121**: 1203-11.
- 481 8. Viswanathan S, Frishman LJ, Robson JG, Walters JW. The photopic negative response of the flash  
482 electroretinogram in primary open angle glaucoma. *Invest Ophthalmol Vis Sci* 2001; **42**: 514-22.
- 483 9. Bui BV, Fortune B. Ganglion cell contributions to the rat full-field electroretinogram. *J Physiol* 2004;  
484 **555**: 153-73.
- 485 10. Colotto A, Falsini B, Salgarello T, Iarossi G, Galan ME, Scullica L. Photopic negative response of the  
486 human ERG: losses associated with glaucomatous damage. *Invest Ophthalmol Vis Sci* 2000; **41**: 2205-  
487 11.
- 488 11. Zhao D, Wong VHY, Nguyen CTO, Jobling AI, Fletcher EL, Vingrys AJ, Bui BV. Reversibility of  
489 Retinal Ganglion Cell Dysfunction From Chronic IOP Elevation. *Invest Ophthalmol Vis Sci* 2019; **60**:  
490 3878-86.

- 491 12. Crowston JG, Kong YX, Trounce IA, Dang TM, Fahy ET, Bui BV, Morrison JC, Chrysostomou V. An  
492 acute intraocular pressure challenge to assess retinal ganglion cell injury and recovery in the mouse.  
493 *Exp Eye Res* 2015; **141**: 3-8.
- 494 13. Fry LE, Fahy E, Chrysostomou V, Hui F, Tang J, van Wijngaarden P, Petrou S, Crowston JG. The  
495 coma in glaucoma: Retinal ganglion cell dysfunction and recovery. *Prog Retin Eye Res* 2018; **65**: 77-  
496 92.
- 497 14. Kong YX, van Bergen N, Bui BV, Chrysostomou V, Vingrys AJ, Trounce IA, Crowston JG. Impact of  
498 aging and diet restriction on retinal function during and after acute intraocular pressure injury.  
499 *Neurobiol Aging* 2012; **33**: 1126 e15-25.
- 500 15. Chrysostomou V, Galic S, van Wijngaarden P, Trounce IA, Steinberg GR, Crowston JG. Exercise  
501 reverses age-related vulnerability of the retina to injury by preventing complement-mediated synapse  
502 elimination via a BDNF-dependent pathway. *Aging Cell* 2016.
- 503 16. Crowston JG, Fahy ET, Fry L, Trounce IA, van Wijngaarden P, Petrou S, Chrysostomou V. Targeting  
504 retinal ganglion cell recovery. *Eye (Lond)* 2017; **31**: 196-8.
- 505 17. Tang J, Hui F, Hadoux X, Sarossy M, van Wijngaarden P, Coote M, Crowston JG. A Comparison of  
506 the RETeval Sensor Strip and DTL Electrode for Recording the Photopic Negative Response. *Transl  
507 Vis Sci Technol* 2018; **7**: 27.
- 508 18. Tang J, Hui F, Coote M, Crowston JG, Hadoux X. Baseline Detrending for the Photopic Negative  
509 Response. *Transl Vis Sci Technol* 2018; **7**: 9.
- 510 19. Fivenson EM, Lautrup S, Sun N, Scheibye-Knudsen M, Stevnsner T, Nilsen H, Bohr VA, Fang EF.  
511 Mitophagy in neurodegeneration and aging. *Neurochem Int* 2017.
- 512 20. Lee S, Sheck L, Crowston JG, Van Bergen NJ, O'Neill EC, O'Hare F, Kong YX, Chrysostomou V,  
513 Vincent AL, Trounce IA. Impaired complex-I-linked respiration and ATP synthesis in primary open-  
514 angle glaucoma patient lymphoblasts. *Invest Ophthalmol Vis Sci* 2012; **53**: 2431-7.
- 515 21. Osborne NN, del Olmo-Aguado S. Maintenance of retinal ganglion cell mitochondrial functions as a  
516 neuroprotective strategy in glaucoma. *Curr Opin Pharmacol* 2013; **13**: 16-22.
- 517 22. van de Ven RA, Santos D, Haigis MC. Mitochondrial Sirtuins and Molecular Mechanisms of Aging.  
518 *Trends Mol Med* 2017; **23**: 320-31.

- 519 23. Mills KF, Yoshida S, Stein LR, Grozio A, Kubota S, Sasaki Y, Redpath P, Migaud ME, Apte RS,  
520 Uchida K, Yoshino J, Imai SI. Long-Term Administration of Nicotinamide Mononucleotide Mitigates  
521 Age-Associated Physiological Decline in Mice. *Cell Metab* 2016; **24**: 795-806.
- 522 24. Srivastava S. Emerging therapeutic roles for NAD(+) metabolism in mitochondrial and age-related  
523 disorders. *Clin Transl Med* 2016; **5**: 25.
- 524 25. Williams PA, Harder JM, John SWM. Glaucoma as a Metabolic Optic Neuropathy: Making the Case  
525 for Nicotinamide Treatment in Glaucoma. *J Glaucoma* 2017; **26**: 1161-8.
- 526 26. Kouassi Nzoughe J, Chao de la Barca JM, Guehlouz K, Leruez S, Coulbault L, Allouche S, Bocca C,  
527 Muller J, Amati-Bonneau P, Gohier P, Bonneau D, Simard G, Milea D, Lenaers G, Procaccio V,  
528 Reynier P. Nicotinamide Deficiency in Primary Open-Angle Glaucoma. *Invest Ophthalmol Vis Sci*  
529 2019; **60**: 2509-14.
- 530 27. Williams PA, Harder JM, Foxworth NE, Cochran KE, Philip VM, Porciatti V, Smithies O, John SW.  
531 Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice. *Science* 2017;  
532 **355**: 756-60.
- 533 28. Chen AC, Martin AJ, Choy B, Fernandez-Penas P, Dalziel RA, McKenzie CA, Scolyer RA, Dhillon  
534 HM, Vardy JL, Kriker A, St George G, Chinniah N, Halliday GM, Damian DL. A Phase 3  
535 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. *N Engl J Med* 2015; **373**: 1618-  
536 26.
- 537 29. Knip M, Douek IF, Moore WP, Gillmor HA, McLean AE, Bingley PJ, Gale EA, European  
538 Nicotinamide Diabetes Intervention Trial G. Safety of high-dose nicotinamide: a review. *Diabetologia*  
539 2000; **43**: 1337-45.
- 540 30. Johnson CA, Keltner JL, Cello KE, Edwards M, Kass MA, Gordon MO, Budenz DL, Gaasterland DE,  
541 Werner E, Ocular Hypertension Study G. Baseline visual field characteristics in the ocular  
542 hypertension treatment study. *Ophthalmology* 2002; **109**: 432-7.
- 543 31. Musch DC, Lichter PR, Guire KE, Standardi CL. The Collaborative Initial Glaucoma Treatment Study:  
544 study design, methods, and baseline characteristics of enrolled patients. *Ophthalmology* 1999; **106**:  
545 653-62.
- 546 32. Hui F, Tang J, Hadoux X, Coote M, Crowston JG. Optimizing a Portable ERG Device for Glaucoma  
547 Clinic: The Effect of Interstimulus Frequency on the Photopic Negative Response. *Transl Vis Sci*  
548 *Technol* 2018; **7**: 26.

- 549 33. Fulton AB, Hansen RM. Scotopic stimulus/response relations of the B-wave of the electroretinogram.  
550 *Doc Ophthalmol* 1988; **68**: 293-304.
- 551 34. Binns AM, Mortlock KE, North RV. The relationship between stimulus intensity and response  
552 amplitude for the photopic negative response of the flash electroretinogram. *Doc Ophthalmol* 2011;  
553 **122**: 39-52.
- 554 35. Joshi NR, Ly E, Viswanathan S. Intensity response function of the photopic negative response (PhNR):  
555 effect of age and test-retest reliability. *Doc Ophthalmol* 2017; **135**: 1-16.
- 556 36. Gardiner SK, Demirel S, Johnson CA, Swanson WH. Assessment of linear-scale indices for perimetry  
557 in terms of progression in early glaucoma. *Vision Res* 2011; **51**: 1801-10.
- 558 37. Garway-Heath DF, Holder GE, Fitzke FW, Hitchings RA. Relationship between electrophysiological,  
559 psychophysical, and anatomical measurements in glaucoma. *Invest Ophthalmol Vis Sci* 2002; **43**: 2213-  
560 20.
- 561 38. Wellek S, Blettner M. On the proper use of the crossover design in clinical trials: part 18 of a series on  
562 evaluation of scientific publications. *Dtsch Arztebl Int* 2012; **109**: 276-81.
- 563 39. Sehi M, Grewal DS, Goodkin ML, Greenfield DS. Reversal of retinal ganglion cell dysfunction after  
564 surgical reduction of intraocular pressure. *Ophthalmology* 2010; **117**: 2329-36.
- 565 40. Ventura LM, Porciatti V. Restoration of retinal ganglion cell function in early glaucoma after  
566 intraocular pressure reduction: a pilot study. *Ophthalmology* 2005; **112**: 20-7.
- 567 41. Evans DW, Hosking SL, Gherghel D, Bartlett JD. Contrast sensitivity improves after brimonidine  
568 therapy in primary open angle glaucoma: a case for neuroprotection. *Br J Ophthalmol* 2003; **87**: 1463-5.
- 569 42. Shibeb O, Chidlow G, Han G, Wood JP, Casson RJ. Effect of subconjunctival glucose on retinal  
570 ganglion cell survival in experimental retinal ischaemia and contrast sensitivity in human glaucoma.  
571 *Clin Exp Ophthalmol* 2016; **44**: 24-32.
- 572 43. Wright TM, Goharian I, Gardiner SK, Sehi M, Greenfield DS. Short-term enhancement of visual field  
573 sensitivity in glaucomatous eyes following surgical intraocular pressure reduction. *Am J Ophthalmol*  
574 2015; **159**: 378-85 e1.
- 575 44. Caprioli J, de Leon JM, Azarbod P, Chen A, Morales E, Nouri-Mahdavi K, Coleman A, Yu F, Afifi A.  
576 Trabeculectomy Can Improve Long-Term Visual Function in Glaucoma. *Ophthalmology* 2016; **123**:  
577 117-28.
- 578 45. Katsyuba E, Auwerx J. Modulating NAD<sup>+</sup> metabolism, from bench to bedside. *EMBO J* 2017.

- 579 46. Williams PA, Harder JM, Cardozo BH, Foxworth NE, John SWM. Nicotinamide treatment robustly  
580 protects from inherited mouse glaucoma. *Commun Integr Biol* 2018; **11**: e1356956.
- 581 47. Kamel K, Farrell M, O'Brien C. Mitochondrial dysfunction in ocular disease: Focus on glaucoma.  
582 *Mitochondrion* 2017; **35**: 44-53.
- 583 48. Domanico D, Verboschi F, Altimari S, Zompatori L, Vingolo EM. Ocular Effects of Niacin: A Review  
584 of the Literature. *Med Hypothesis Discov Innov Ophthalmol* 2015; **4**: 64-71.
- 585 49. Schwartz JB. The current state of knowledge on age, sex, and their interactions on clinical  
586 pharmacology. *Clinical pharmacology and therapeutics* 2007; **82**: 87-96.
- 587 50. Petley A, Macklin B, Renwick AG, Wilkin TJ. The pharmacokinetics of nicotinamide in humans and  
588 rodents. *Diabetes* 1995; **44**: 152-5.
- 589